Accelerated Approval Drug Promotions Run Risk Of Overstating Efficacy, Understating Safety

Sponsors needs to think carefully about what to say in product promotions when clinical benefit has not yet been demonstrated, legal and regulatory experts said; such communications may or may not be able to leverage US FDA guidances on ‘consistent with labeling’ (CFL) and scientific information on unapproved uses (SIUU).